Cargando…
Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma
INTRODUCTION: Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regime...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913158/ https://www.ncbi.nlm.nih.gov/pubmed/24505545 |
_version_ | 1782302188408668160 |
---|---|
author | Samimi, Mozhgan Aalam Mirkheshti, Nooshin Pazouki, Abdolreza |
author_facet | Samimi, Mozhgan Aalam Mirkheshti, Nooshin Pazouki, Abdolreza |
author_sort | Samimi, Mozhgan Aalam |
collection | PubMed |
description | INTRODUCTION: Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these patients. METHOD AND MATERIALS: We investigated 15 patients aged 15 to 40 years old and used continuous infusion of cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. Percent of necrosis and toxicities was recorded for each patient. RESULTS: Out of 15 patients investigated, 13 were males and 2 females. Tumor necrosis≥ 90% (defined as good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four. CONCLUSION: The above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens including high dose of MTX with reduced toxicity and less nursing cares and laboratory tests. Of course small sample size limits extension of our result to all patients but trying this regimen is recommended in more patients to see more reliable results. |
format | Online Article Text |
id | pubmed-3913158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-39131582014-02-06 Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma Samimi, Mozhgan Aalam Mirkheshti, Nooshin Pazouki, Abdolreza Int J Hematol Oncol Stem Cell Res Original Article INTRODUCTION: Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these patients. METHOD AND MATERIALS: We investigated 15 patients aged 15 to 40 years old and used continuous infusion of cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. Percent of necrosis and toxicities was recorded for each patient. RESULTS: Out of 15 patients investigated, 13 were males and 2 females. Tumor necrosis≥ 90% (defined as good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four. CONCLUSION: The above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens including high dose of MTX with reduced toxicity and less nursing cares and laboratory tests. Of course small sample size limits extension of our result to all patients but trying this regimen is recommended in more patients to see more reliable results. Tehran University of Medical Sciences 2014 /pmc/articles/PMC3913158/ /pubmed/24505545 Text en © 2014 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Samimi, Mozhgan Aalam Mirkheshti, Nooshin Pazouki, Abdolreza Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title | Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title_full | Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title_fullStr | Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title_full_unstemmed | Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title_short | Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma |
title_sort | assessing the percent of necrosis after neoadjuvant chemotherapy with 24hr infusional cisplatin/3 days doxorubicin intermittent with ifosfamide-doxorubicin for osteosarcoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913158/ https://www.ncbi.nlm.nih.gov/pubmed/24505545 |
work_keys_str_mv | AT samimimozhganaalam assessingthepercentofnecrosisafterneoadjuvantchemotherapywith24hrinfusionalcisplatin3daysdoxorubicinintermittentwithifosfamidedoxorubicinforosteosarcoma AT mirkheshtinooshin assessingthepercentofnecrosisafterneoadjuvantchemotherapywith24hrinfusionalcisplatin3daysdoxorubicinintermittentwithifosfamidedoxorubicinforosteosarcoma AT pazoukiabdolreza assessingthepercentofnecrosisafterneoadjuvantchemotherapywith24hrinfusionalcisplatin3daysdoxorubicinintermittentwithifosfamidedoxorubicinforosteosarcoma |